search
Back to results

Watch and Wait Management on Rectal Cancer Patients Using New Swift Local Therapy (Whistle)

Primary Purpose

Rectal Cancer, Comorbidities and Coexisting Conditions, Inoperable Disease

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
External beam radiotherapy + Endorectal brachytherapy
Sponsored by
Sir Mortimer B. Davis - Jewish General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rectal Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with histologic diagnosis by proctoscopic biopsy of invasive rectal adenocarcinoma will be considered for entry in this study.
  • Patient in whom the diagnosis of invasive rectal cancer has been obtained by incisional biopsy (surgical or endoscopic biopsy) that the majority of the tumor has not been removed .
  • The tumor should be either palpable by clinical rectal exam or accessible via a rigid proctoscope, and its proximal border should be located no more than 15 cm from the anal verge.
  • Rectal cancer clinically stage as T2-T3 N1+ by MRI or endoscopic ultrasound.
  • Tumor of 5 cm or less length, non obstructive
  • Patient is not suitable for surgery nor chemotherapy due to medical conditions
  • Patient must consent to be in the study and consent form must be signed, witnessed and dated prior to registration .
  • Patients must be accessible geographically for follow up.
  • Adults older than 18 years of age

Exclusion Criteria:

  • Patient with malignant rectal tumors other than adenocarcinoma, i.e, sarcoma, lymphoma, carcinoid, squamous cell, cloacogenic, etc.
  • Patient who demonstrate prior to randomization, evidence of free perforation, as manifested by free fluid in the abdomen.
  • Patient who are curable by standard of care with either surgery or eligible for the Morpheus study.
  • Patient who have received any previous therapy (radiation , chemotherapy) for rectal cancer.
  • Patient whose tumor is fixed by clinical examination to surrounding structures, precluding the possibility of adequate surgical resection even with pelvic exenteration.
  • Patient with a performance status of 3 or 4.
  • Patient with tumor involving the anal canal.
  • Patient who are pregnant at the time of randomization.
  • Patient with psychiatric or addictive disorders that would preclude obtaining informed consent.
  • Patient who have multiple primary tumors involving both the colon and rectum that would preclude them from being classified as having only rectal cancer.

Sites / Locations

  • Jewish General HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

External beam radiotherapy + Endorectal brachytherapy

Arm Description

In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.

Outcomes

Primary Outcome Measures

The feasibility of the new device
To measure the percentage (%) of clinical complete responders versus non-complete clinical responders and compare it to the percentage of an already proven device to determine if the new device can be used to treat rectal cancer patients. The cancer response will be assessed by rectoscopy, biopsy and imaging.
Toxicity using the new device
Use the CTCAE guidelines to measure the percentage (%) of toxicity (G3 and above) of this novel X-Ray device. All grade 3 post-treatment complications will be reported (Proctitis, rectal bleeding, diarrhea). The toxicity will be assessed by the clinician during the follow-up visits. An early stopping rule for possible severe toxicity during and post treatment toxicity will be used in this study. The following early stopping rules will be applied to test the null hypothesis that the proportion of severe toxicity is less or equal to 25 % at 0.05: 3 severe toxicities (G3-4) out of the first 12 evaluable patients or 5 severe toxicities (G3-4) out of the first 22 evaluable patients or 7 severe toxicities (G3-4) out of the first 36 evaluable patients.
Workload
To evaluate the workload of this modality in regards to time management (the time required to treat patients (pre-treatment and during treatment) and the number of ressources required. The principal investigator will compare it to an already existent equivalent treatment.

Secondary Outcome Measures

Tumor response
Number of participants (#) that are complete clinical responders
Local control
Number (#) of participants with Local control assessed during follow-up visits

Full Information

First Posted
February 20, 2020
Last Updated
May 23, 2023
Sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Collaborators
Icad, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04336202
Brief Title
Watch and Wait Management on Rectal Cancer Patients Using New Swift Local Therapy
Acronym
Whistle
Official Title
A Pilot Study of Dose-escalation Strategy of Radiotherapy Followed by Endorectal Brachytherapy With the Use of a New Rectal Applicator in Inoperable, Ederly Rectal Cancer Patients
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 2023 (Anticipated)
Primary Completion Date
February 2025 (Anticipated)
Study Completion Date
January 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Collaborators
Icad, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Within our institution, the principal investigator have acquired expertise in endorectal brachytherapy, a localized treatment for colorectal cancer. Until now a modality which uses an endorectal applicator has been used, which has certain limitations. In the context of this study, a new applicator will be used which is already approved by Health Canada for endorectal brachytherapy, thereby improving the participant's quality of life and optimizing treatment time.
Detailed Description
The main goal of this study is to treat patients using external beam radiotherapy followed by endorectal brachytherapy using a new applicator. Validating the feasibility of this new applicator, assessing the treatment time required when using it, the necessary workload required and ultimately avoid the need for surgery are our main priorities. Currently, this option is still experimental, although several patients have been treated with this method during the last ten years. In this pilot study, 45 patients will be recruited, whom have medical conditions (co-morbidities) that make surgery very difficult, or patients that are refusing surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Cancer, Comorbidities and Coexisting Conditions, Inoperable Disease, Brachytherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
45 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
External beam radiotherapy + Endorectal brachytherapy
Arm Type
Other
Arm Description
In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
Intervention Type
Radiation
Intervention Name(s)
External beam radiotherapy + Endorectal brachytherapy
Intervention Description
In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
Primary Outcome Measure Information:
Title
The feasibility of the new device
Description
To measure the percentage (%) of clinical complete responders versus non-complete clinical responders and compare it to the percentage of an already proven device to determine if the new device can be used to treat rectal cancer patients. The cancer response will be assessed by rectoscopy, biopsy and imaging.
Time Frame
2 years post treatment
Title
Toxicity using the new device
Description
Use the CTCAE guidelines to measure the percentage (%) of toxicity (G3 and above) of this novel X-Ray device. All grade 3 post-treatment complications will be reported (Proctitis, rectal bleeding, diarrhea). The toxicity will be assessed by the clinician during the follow-up visits. An early stopping rule for possible severe toxicity during and post treatment toxicity will be used in this study. The following early stopping rules will be applied to test the null hypothesis that the proportion of severe toxicity is less or equal to 25 % at 0.05: 3 severe toxicities (G3-4) out of the first 12 evaluable patients or 5 severe toxicities (G3-4) out of the first 22 evaluable patients or 7 severe toxicities (G3-4) out of the first 36 evaluable patients.
Time Frame
2 years post treatment
Title
Workload
Description
To evaluate the workload of this modality in regards to time management (the time required to treat patients (pre-treatment and during treatment) and the number of ressources required. The principal investigator will compare it to an already existent equivalent treatment.
Time Frame
2 years post treatment
Secondary Outcome Measure Information:
Title
Tumor response
Description
Number of participants (#) that are complete clinical responders
Time Frame
At clinical evaluation, 13 weeks since beginning of treatments
Title
Local control
Description
Number (#) of participants with Local control assessed during follow-up visits
Time Frame
2 years post treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with histologic diagnosis by proctoscopic biopsy of invasive rectal adenocarcinoma will be considered for entry in this study. Patient in whom the diagnosis of invasive rectal cancer has been obtained by incisional biopsy (surgical or endoscopic biopsy) that the majority of the tumor has not been removed . The tumor should be either palpable by clinical rectal exam or accessible via a rigid proctoscope, and its proximal border should be located no more than 15 cm from the anal verge. Rectal cancer clinically stage as T2-T3 N1+ by MRI or endoscopic ultrasound. Tumor of 5 cm or less length, non obstructive Patient is not suitable for surgery nor chemotherapy due to medical conditions Patient must consent to be in the study and consent form must be signed, witnessed and dated prior to registration . Patients must be accessible geographically for follow up. Adults older than 18 years of age Exclusion Criteria: Patient with malignant rectal tumors other than adenocarcinoma, i.e, sarcoma, lymphoma, carcinoid, squamous cell, cloacogenic, etc. Patient who demonstrate prior to randomization, evidence of free perforation, as manifested by free fluid in the abdomen. Patient who are curable by standard of care with either surgery or eligible for the Morpheus study. Patient who have received any previous therapy (radiation , chemotherapy) for rectal cancer. Patient whose tumor is fixed by clinical examination to surrounding structures, precluding the possibility of adequate surgical resection even with pelvic exenteration. Patient with a performance status of 3 or 4. Patient with tumor involving the anal canal. Patient who are pregnant at the time of randomization. Patient with psychiatric or addictive disorders that would preclude obtaining informed consent. Patient who have multiple primary tumors involving both the colon and rectum that would preclude them from being classified as having only rectal cancer.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Te Vuong, MD
Phone
514-340-8288
Email
tvuong@jgh.mcgill.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Luciana Poggi, PhD
Phone
514-340-8222
Ext
28443
Email
luciana.poggi.trinidad.ccomtl@ssss.gouv.qc.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Te Vuong, MD
Organizational Affiliation
Sir Mortimer B. Davis - Jewish General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jewish General Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luciana Poggi, PhD
Phone
514-340-8222
Email
luciana.poggi.trinidad.ccomtl@ssss.gouv.qc.ca
First Name & Middle Initial & Last Name & Degree
Te Vuong, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
18452860
Citation
Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008 May;9(5):494-501. doi: 10.1016/S1470-2045(08)70129-3.
Results Reference
background
PubMed Identifier
21445672
Citation
Dekker JW, van den Broek CB, Bastiaannet E, van de Geest LG, Tollenaar RA, Liefers GJ. Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients. Ann Surg Oncol. 2011 Jun;18(6):1533-9. doi: 10.1245/s10434-011-1671-x. Epub 2011 Mar 29.
Results Reference
background
PubMed Identifier
31476417
Citation
Garant A, Magnan S, Devic S, Martin AG, Boutros M, Vasilevsky CA, Ferland S, Bujold A, DesGroseilliers S, Sebajang H, Richard C, Vuong T. Image Guided Adaptive Endorectal Brachytherapy in the Nonoperative Management of Patients With Rectal Cancer. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1005-1011. doi: 10.1016/j.ijrobp.2019.08.042. Epub 2019 Aug 30.
Results Reference
background
PubMed Identifier
29102741
Citation
Liang LH, Tomic N, Vuong T, Aldelaijan S, Bekerat H, DeBlois F, Seuntjens J, Devic S. Physics aspects of the Papillon technique-Five decades later. Brachytherapy. 2018 Jan-Feb;17(1):234-243. doi: 10.1016/j.brachy.2017.09.016.
Results Reference
background
PubMed Identifier
12182984
Citation
Gerard JP, Chapet O, Ramaioli A, Romestaing P. Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):142-9. doi: 10.1016/s0360-3016(02)02879-1.
Results Reference
background
PubMed Identifier
28937269
Citation
Sun Myint A, Smith FM, Gollins SW, Wong H, Rao C, Whitmarsh K, Sripadam R, Rooney P, Hershman MJ, Fekete Z, Perkins K, Pritchard DM. Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation? Br J Radiol. 2017 Dec;90(1080):20170175. doi: 10.1259/bjr.20170175. Epub 2017 Nov 10.
Results Reference
background

Learn more about this trial

Watch and Wait Management on Rectal Cancer Patients Using New Swift Local Therapy

We'll reach out to this number within 24 hrs